

Liver Forum 15

Wednesday, September 6, 2023

Institut Pasteur

NEW ENTRANCE ACCESS

205 rue de Vaugirard

75015 Paris, FRANCE

<https://www.pasteur.fr/en>

AGENDA

12:00	Registration & Lunch	
12:30	Session I: Welcome & Introductory Remarks	
12:30	Introductory Remarks	<i>Veronica Miller, Arun Sanyal, & Judith Ertle</i>
12:35	Review of Liver Forum 15 Goals and Objectives	<i>Veronica Miller, Forum for Collaborative Research</i>
12:45	Session II: Steatotic Liver Diseases: Review of New Nomenclature from Multi-Stakeholders Perspectives	
	Moderators: Veronica Miller and Jörn Schattenberg*	
12:45	Overview of Nomenclature Consensus, Challenges, and the Future	<i>Arun Sanyal, Virginia Commonwealth University; Meena Bansal, Mount Sinai Hospital, NY; Sven Francque*, University of Antwerp, Belgium; George Makar*, FDA; Joachim Musaus, EMA; Don Chalfin, Patient; Henry Chang*, Fatty Liver Foundation; Michelle Long, NovoNordisk; Judith Ertle, Boehringer Ingelheim</i>
13:35	General Discussion	
14:05	Session III: Advances in Digital Pathology & AI/ML for MASH	
	Moderator: Arun Sanyal	
14:05	The Role of AI/ML in MASH Digital Pathology	<i>Dean Tai, HistoIndex</i>
14:20	The Role of AI/ML in MASH Digital Pathology	<i>Janani Iyer & Katy Wack*, PathAI</i>
14:35	The Role of AI/ML in MASH Digital Pathology	<i>Mathieu Petitjean, PharmaNest</i>
14:50	The Role of AI/ML in MASH Digital Pathology	<i>Cindy Serdjebi, BioCellvia</i>
15:05	General Discussion	
15:35	Break	

*Remote participation

16:05	Session IV: Moving Forward with NITs	
	Moderators: Laurent Castera & Meena Bansal	
16:05	Brief Overview of Liver Forum Work in NITs	<i>Veronica Miller, Forum for Collaborative Research</i>
16:10	FDA NIT Workshop: Open Invitation	<i>Abbas Bandukwala*, US Food and Drug Administration</i>
16:15	Proposal to the Liver Forum: 1) Consensus on non-invasive marker data to collect and report 2) Designing NIT-based trials	<i>Quentin Anstee*, Newcastle University</i>
16:30	Panel Discussion	<i>Manal Abdelmalek*, Mayo Clinic; Vlad Ratziu, Sorbonne University; Claudia Filozof, Fortrea; Corinna Schoelch, Boehringer Ingelheim; Michael Betel, Fatty Liver Alliance; Michael Middleton, UC San Diego</i>
17:00	Session V: Stretch Exercise: Pragmatic Benefit-Risk Assessment for Diagnostics	
	Moderator: Veronica Miller	
17:00	A New Look at Benefit-Risk in Diagnostics	<i>Scott Evans, George Washington University</i>
17:20	General Discussion	
17:30	Session VI: Working Group Updates and Proposals	
17:30	MASH (NASH) Placebo Arm Database	<i>Michael Cooreman, Inventiva Pharma</i>
17:40	Combination Therapy	<i>Michelle Long, Novo Nordisk</i>
17:50	Pooling of Endpoints Across Trials	<i>Michelle Long, Novo Nordisk</i>
18:00	Discussant	<i>Laurent Castera, Université Paris Cite Hôpital Beaujon</i>
18:05	New Working Group: Radiology Liver Diseases (RLD) Program	<i>Michael Middleton, UC San Diego</i>
18:20	New Working Group: Intersection of Steatotic Liver Disease (SLD) and Alcohol Liver Disease (ALD)- Met-ALD	<i>Nikhil Vergis, GlaxoSmithKline</i>
18:35	Discussants:	<i>Donna Cryer, Global Liver Institute & Roberto Calle*, Regeneron</i>
18:40	Closing Remarks	
18:40	Wrap Up	<i>Arun Sanyal, Virginia Commonwealth University; Judith Ertle, Boehringer Ingelheim; Veronica Miller, Forum for Collaborative Research</i>
18:45	Adjourn & Reception	

*Remote participation